Innoviva Stock

Innoviva EBIT per Employee

The EBIT per Employee of Innoviva (INVA) as of Aug 6, 2026 is 32.75 M USD. In the previous year, EBIT per Employee was 11.92 M USD — a change of 174.75% (higher).

EBIT per Employee

32.75 MUSD

YoY

174.75%

Last updated:

EBIT per Employee of Innoviva is 2026 32.75 M USD. EBIT per Employee of Innoviva was 2025 11.92 M USD. It decreases by 174.75% higher compared to the previous year.
Access this data via the Eulerpool API

Innoviva Stock analysis

What does Innoviva do? Innoviva Inc - An innovative story Innoviva Inc is a US-based company specializing in the development and marketing of therapy and diagnostic products for respiratory diseases. The company was founded in 1996 under the name Theravance Inc and was renamed Innoviva Inc in 2016. The story of Innoviva Inc began with the goal of developing innovative therapies for chronic respiratory diseases. Over the years, the company expanded and diversified its product portfolio. Today, Innoviva Inc is a leading provider of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Business model of Innoviva Inc The business model of Innoviva Inc is based on the development of products for the treatment of respiratory diseases and collaboration with other pharmaceutical and biotech companies. The company licenses its products to partner companies, which distribute them in the market. This way, Innoviva Inc generates revenue from licensing fees and milestone payments. Divisions of Innoviva Inc Innoviva Inc is divided into three divisions: development, licensing, and financing. The development division is responsible for researching and developing new therapy and diagnostic products. The company works closely with other pharmaceutical and biotech companies in this regard. The licensing division is responsible for licensing products to partner companies. This includes negotiating license agreements and conducting clinical trials. The financing division of Innoviva Inc is responsible for raising external capital. This includes issuing bonds and seeking investment. Products of Innoviva Inc Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. These include: - RELVAR®/BREO® (Fluticasone furoate/Vilanterol) for the treatment of COPD and asthma - ANORO® (Umeclidinium bromide/Vilanterol) for the treatment of COPD - TRELEGY® (Fluticasone furoate/Umeclidinium bromide/Vilanterol) for the treatment of COPD These products have been developed by Innoviva Inc and are licensed to partner companies for distribution. Innoviva Inc is an innovative company specializing in the development and marketing of products for the treatment of respiratory diseases. The business model is based on the development of products and licensing them to partner companies. Innoviva Inc has a wide range of therapy and diagnostic products for respiratory diseases. Innoviva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innoviva stock

EBIT per Employee of Innoviva is 32.75 M USD in 2026.

EBIT per Employee of Innoviva changed from 11.92 M USD to 32.75 M USD, representing a 174.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Innoviva since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Innoviva historically and in real time.

Access this data via the Eulerpool API

Workforce — Innoviva

All Key Metrics — Innoviva